Oral, rat: LD50 = 318 mg/kg. Signs of overdose include fast or irregular heartbeat, mental or mood changes, tightness in the chest, and unusual tiredness or weakness.
Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Brompheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine. |
| Magnesium sulfate | The therapeutic efficacy of Brompheniramine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Brompheniramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Brompheniramine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine. |
| Mirtazapine | Brompheniramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine. |
| Orphenadrine | Brompheniramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Brompheniramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine. |
| Pramipexole | Brompheniramine may increase the sedative activities of Pramipexole. |
| Ropinirole | Brompheniramine may increase the sedative activities of Ropinirole. |
| Rotigotine | Brompheniramine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Brompheniramine. |
| Sodium oxybate | Brompheniramine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Brompheniramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine. |
| Thalidomide | Brompheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Brompheniramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Aclidinium | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Brompheniramine. |
| Mirabegron | The risk or severity of urinary retention can be increased when Brompheniramine is combined with Mirabegron. |
| Potassium chloride | The risk or severity of gastrointestinal ulceration can be increased when Brompheniramine is combined with Potassium chloride. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Brompheniramine. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Brompheniramine. |
| Tiotropium | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Brompheniramine is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Umeclidinium. |
| Benzylpenicilloyl polylysine | Brompheniramine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Brompheniramine. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Brompheniramine. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Brompheniramine. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Brompheniramine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Brompheniramine. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Glycopyrronium. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Botulinum toxin type A. |
| Glucagon | Brompheniramine may increase the gastrointestinal motility reducing activities of Glucagon. |
| Sulpiride | Brompheniramine may increase the anticholinergic activities of Sulpiride. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Botulinum toxin type B. |
| Eluxadoline | The risk or severity of constipation can be increased when Brompheniramine is combined with Eluxadoline. |
| Ramosetron | The risk or severity of constipation can be increased when Brompheniramine is combined with Ramosetron. |
| Ethanol | Brompheniramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Brompheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Fluvoxamine. |
| Duloxetine | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Paroxetine. |
| Sibutramine | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Sibutramine. |
| Zimelidine | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of Tachycardia can be increased when Brompheniramine is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Alaproclate. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Citalopram. |
| Escitalopram | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Escitalopram. |
| Nefazodone | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Nefazodone. |
| Amphetamine | Amphetamine may decrease the sedative activities of Brompheniramine. |
| Phentermine | Phentermine may decrease the sedative activities of Brompheniramine. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Brompheniramine. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Brompheniramine. |
| Lisdexamfetamine | Lisdexamfetamine may decrease the sedative activities of Brompheniramine. |
| Mephentermine | Mephentermine may decrease the sedative activities of Brompheniramine. |
| MMDA | MMDA may decrease the sedative activities of Brompheniramine. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Brompheniramine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Brompheniramine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Brompheniramine. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Brompheniramine. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Brompheniramine. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Brompheniramine. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Brompheniramine. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Brompheniramine. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Brompheniramine. |
| Ritobegron | Ritobegron may decrease the sedative activities of Brompheniramine. |
| Mephedrone | Mephedrone may decrease the sedative activities of Brompheniramine. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of Brompheniramine. |
| Gepefrine | Gepefrine may decrease the sedative activities of Brompheniramine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Brompheniramine. |
| Phendimetrazine | Phendimetrazine may decrease the sedative activities of Brompheniramine. |
| Naltrexone | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Bezitramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Desomorphine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Nicomorphine. |
| Morphine | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Morphine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Hydromorphone. |
| Oxycodone | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Sufentanil. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Remifentanil. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Brompheniramine is combined with Diphenoxylate. |